跳至主要内容
临床试验/ITMCTR2000004171
ITMCTR2000004171招募中4 期

Explore the best time for ATO to treat PV combined with compound Huangdai tablets

Southern Hospital0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

性别
All

入选标准

  • 1. Aged 14–75 years, Newly diagnosed PV with t(15; 17)(q22; q12);
  • 2. Pre-treatment peripheral blood white blood cell(WBC) count < 10 x 10^9/L;
  • 3. Able to complete the entire treatment process;
  • 4. Signed written informed consent provided by the patient or their family.

排除标准

  • 1. Allergy to the drug ingredient or the supplementary material, or having an allergic constitution;
  • 2. Cardiac insufficiency (cardiac contraindications: left-ventricular ejection fraction (L-VEF) < 50%));
  • 3. Inadequate renal reserve (defined as total creatinine > 3 times the institutional upper limit of the normal range);
  • 4. Significant arrhythmias, electrocardiogram (EKG) abnormalities (congenital long QT syndrome; history or presence of significant ventricular or atrial tachyarrhythmia; clinically significant resting bradycardia (< 50 beats per minute);
  • QTc > 450 ms on screening EKG; right bundle branch block plus left anterior hemiblock, bifascicular block);
  • 5. Combined with other malignant tumors;
  • 6. Pregnant and lactating women;
  • 7. Participants in other drug trials in the last 3 months;
  • 8. Suffering from mental illness or other circumstances which render them unable to complete the treatment plan.

研究者

发起方
Southern Hospital

相似试验